Movement disorders:血管周间隙和帕金森病 关系密切

2022-11-25 Freeman MedSci原创 发表于广东省

小的BG-PVS与日常生活中的运动和非运动方面的经验有关

血管周围空间(PVS)是大脑血管周围充满液体的空间,是大脑液体和淋巴废物清除系统的重要通道。在神经退行性疾病患者和研究淀粉样蛋白清除的小鼠模型中,有临床和前临床证据表明,磁共振成像(MRI)上可见的PVS是脑小血管疾病和糖液清除功能障碍的标志。

图1: 论文封面图

除了MRI可见的PVS外,其他成熟的基于神经影像学的脑小血管疾病的标志物包括脑室周围和深部白质增生(WMHs)。

在帕金森病(PD)中,基底神经节区域的PVS负担(BG-PVS)已被认为是运动障碍和认知衰退进展的潜在指标。然而,有关认知方面的研究结果不一,有些研究报告说与PVS视觉负担得分没有明显的相关性。不幸的是,这些研究中有许多是用定性的视觉评分量表来评估BG-PVS的,而这种量表更容易受到评分者偏差以及上限和下限效应的影响。

有趣的是,两项基于人群的大型研究表明,大的(直径>3毫米)与小的(直径≤3毫米)PVS之间存在着病理生理上的差异,尽管在PD中没有具体证明。北曼哈顿研究的结果表明,小PVS的高负担与未来血管事件的风险增加有关,而AGES-Reykjavik研究显示,大PVS与信息处理速度下降和痴呆风险增加有关。

藉此,多伦多大学的Joel Ramirez等人, 在一个多中心的PD患者队列中,探究大型和小型BG-PVS的定量测量、全局认知和运动/非运动特征之间的关联。

他们考察了安大略省神经退行性疾病研究计划中登记的133名帕金森病患者的大、小BG-PVS与运动障碍协会统一帕金森病评定量表(MDS-UPDRS)I-IV部分和认知(蒙特利尔认知评估)之间的关联。

 


图2:论文结果图


他们发现:小BG-PVS的PD患者与MDS-UPDRS第一部分(P = 0.008)和第二部分(均P = 0.02)有关联,而大BG-PVS的患者与MDS-UPDRS第三部分(P < 0.0001)和第四部分(P < 0.001)有关联。

BG-PVS与认知能力不相关。

该研究的重要意义在于发现了:小的BG-PVS与日常生活中的运动和非运动方面的经验有关,而大的BG-PVS则与运动症状和运动并发症有关。


原文出处:
Ramirez J, Berberian SA, Breen DP, et al. Small and Large Magnetic Resonance Imaging–Visible Perivascular Spaces in the Basal Ganglia of Parkinson’s Disease Patients. _Movement Disorders_. Published online April 11, 2022:mds.29010. doi:[10.1002/mds.29010](https://doi.org/10.1002/mds.29010)

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1878533, encodeId=ac5d18e853314, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Mon Oct 31 00:05:33 CST 2022, time=2022-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784510, encodeId=72801e84510c9, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu May 25 21:05:33 CST 2023, time=2023-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738125, encodeId=aa9f1e381257d, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Jun 13 22:05:33 CST 2022, time=2022-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077692, encodeId=0c4020e769206, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Thu Dec 01 03:05:33 CST 2022, time=2022-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013893, encodeId=9ae8201389353, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Aug 01 19:05:33 CST 2022, time=2022-08-01, status=1, ipAttribution=)]
    2022-10-31 anminleiryan
  2. [GetPortalCommentsPageByObjectIdResponse(id=1878533, encodeId=ac5d18e853314, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Mon Oct 31 00:05:33 CST 2022, time=2022-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784510, encodeId=72801e84510c9, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu May 25 21:05:33 CST 2023, time=2023-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738125, encodeId=aa9f1e381257d, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Jun 13 22:05:33 CST 2022, time=2022-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077692, encodeId=0c4020e769206, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Thu Dec 01 03:05:33 CST 2022, time=2022-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013893, encodeId=9ae8201389353, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Aug 01 19:05:33 CST 2022, time=2022-08-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1878533, encodeId=ac5d18e853314, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Mon Oct 31 00:05:33 CST 2022, time=2022-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784510, encodeId=72801e84510c9, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu May 25 21:05:33 CST 2023, time=2023-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738125, encodeId=aa9f1e381257d, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Jun 13 22:05:33 CST 2022, time=2022-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077692, encodeId=0c4020e769206, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Thu Dec 01 03:05:33 CST 2022, time=2022-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013893, encodeId=9ae8201389353, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Aug 01 19:05:33 CST 2022, time=2022-08-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1878533, encodeId=ac5d18e853314, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Mon Oct 31 00:05:33 CST 2022, time=2022-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784510, encodeId=72801e84510c9, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu May 25 21:05:33 CST 2023, time=2023-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738125, encodeId=aa9f1e381257d, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Jun 13 22:05:33 CST 2022, time=2022-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077692, encodeId=0c4020e769206, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Thu Dec 01 03:05:33 CST 2022, time=2022-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013893, encodeId=9ae8201389353, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Aug 01 19:05:33 CST 2022, time=2022-08-01, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1878533, encodeId=ac5d18e853314, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Mon Oct 31 00:05:33 CST 2022, time=2022-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784510, encodeId=72801e84510c9, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu May 25 21:05:33 CST 2023, time=2023-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738125, encodeId=aa9f1e381257d, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Jun 13 22:05:33 CST 2022, time=2022-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077692, encodeId=0c4020e769206, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Thu Dec 01 03:05:33 CST 2022, time=2022-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013893, encodeId=9ae8201389353, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Aug 01 19:05:33 CST 2022, time=2022-08-01, status=1, ipAttribution=)]

相关威廉亚洲官网

iPSC疗法、新靶点、单细胞测序,帕金森病最新研究进展解读

帕金森病的治疗和诊断一直是十分热门的研究领域,最近帕金森病领域有了一些新的突破。通过这篇文章,williamhill asia 一起了解下帕金森病领域的一些新发现、新进展。

Nature:麻省理工学院冯国平团队揭示帕金森病治疗新靶点,靶向丘脑回路可挽救帕金森病运动和情绪缺陷

药物治疗(L-多巴)和脑深部电刺激是目前治疗帕金森病的主要手段,可以有效地改善肢体震颤等运动症状,但是对于非运动症状,例如情绪紊乱收效甚微。

Neurology:帕金森病患者的运动和非运动症状与健康相关的生活质量的关系

潜在的可治疗的运动和非运动症状,特别是神经精神症状,在PwPD的HRQOL的变化中占了很大一部分。

Movement Disorders:路易体病理和阿尔兹海默病理,如何影响男女的临床表型差异?

使用LB和AD生物标志物,即使在LB或AD病理不在临床预期之内,对于LB疾病和AD的准确临床诊断也是必要的。

Movement Disorders:特发性帕金森病患者尿液中Rab10磷酸化的升高

pT73-Rab10的水平较高与疾病进展的恶化有关。

European Radiology:帕金森病的SMwI MRI前瞻性多中心研究

最近,临床上开发了感光图加权成像(SMwI)技术以改善描绘含铁结构的信噪比和对比度-噪声比。最近的研究进一步表明,SMwI在评估3T下的黑质高浓度方面优于SW。

拓展阅读

MIND饮食:能预防老年痴呆和帕金森病?

健脑饮食,又称 MIND 饮食,是一种针对大脑健康的饮食法,这种饮食相对较新颖,不属于生酮饮食,但是低碳水饮食的一种。它结合了地中海饮食和 DASH 饮食。

Neurology:帕金森病患者结构脑网络弹性和拓扑结构的病理改变

本研究结果强调,区域网络干扰的解释比以前认为的要复杂得多。

BMJ子刊 | 瑞金医院陈生弟教授团队:长期太极拳训练对帕金森病的影响:一项为期 3.5 年的随访队列研究

太极拳训练对帕金森病有长期的有益影响,可以改善运动和非运动症状,减少并发症。

Nat Commun:结合机器学习与血浆蛋白质组质谱分析可提前7年预测帕金森病,准确率达79%

该研究表明,血浆蛋白质组检测或有助于在运动症状出现前7年预测PD的发生。

European Radiology:帕金森病患者脑铁氧代谢的时空变化特征

氧摄取分数(OEF) 是脑氧代谢相关的生理指标,反映脑动脉供血的氧摄取百分比。其中,PD患者脑组织OEF值可作为评估脑氧代谢异常的无创性临床指标。

Brain:多巴胺和深部脑刺激加速帕金森病患者的意愿性动作神经动力学

多巴胺和深部脑刺激通过加速和改变帕金森病患者自愿动作的神经动力学来缓解运动不能,具体表现为将皮质-丘脑底核耦合的振荡信息流从抗运动的β节律转移到促运动的θ节律。

2024 NICE 诊断威廉亚洲博彩公司 :帕金森病远程监测设备 [DG51]

英国国家卫生与临床优化研究所(NICE,National Institute for Health and Clinical Excellence) · 2024-01-25

2023 NICE 技术鉴定威廉亚洲博彩公司 :左旋多巴/卡比多巴组合治疗伴有运动症状的晚期帕金森病[TA934]

英国国家卫生与临床优化研究所(NICE,National Institute for Health and Clinical Excellence) · 2023-11-29

帕金森病患者睡眠障碍评估与护理干预的最佳证据总结

浙江中医药大学护理学院 · 2023-08-10